Zirconium-89-labeled avelumab has been investigated primarily in preclinical studies in which high specificity and affinity to PD-L1 were demonstrated on PD-L1-positive MDA-MB-231 human breast adenocarcinoma cells (78). This evidence concerns the gene CD274 and breast adenocarcinoma.